Clinical trials
Recently updated clinical trials with India locations Check the original source and local guidance before use.
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
September 28, 2026
About this update
This AI summary is based on ClinicalTrials.gov (India locations). The original source link and last refresh date are saved here for you to check.
View official sourceSummary
Phase not stated. Randomized study of a 9-valent ExPEC conjugate vaccine (ExPEC9V; JNJ-78901563/VAC52416) to prevent invasive extraintestinal pathogenic E. coli disease (IED) in adults ≥60 with a urinary tract infection history in the past 2 years. IED is defined by E. coli isolated from blood/sterile sites, or from urine in urosepsis without another source. Design: inferentially seamless group-sequential. Phases: screening (up to 8 days pre–Day 1), randomization, single vaccination (Day 1), and follow-up up to 4 years; total study duration about 6 years 9 months. Rationale notes that conjugate vaccine efficacy is not expected to differ by antimicrobial resistance due to O-polysaccharide targeting. Ongoing; outcomes not reported.
Want to read more?
Create a free account to read the saved source details and open the original source link.
Create free account Already registered? Sign inA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
October 6, 2026
Phase not stated. Randomized study in high-risk, early-stage (non‑metastatic) triple‑negative or HR‑low/HER2‑negative breast cancer. Compares sacituzumab tirumotecan (MK‑2870) plus pembrolizumab and chemotherapy versus pembrolizumab with chemotherapy alone. Primary aims: assess reduction of residual cancer in breast/lymph nodes at surgery and determine whether adding MK‑2870 improves time without cancer growth, spread, or return. Targeted therapy mechanism is described generally; specific efficacy and safety outcomes are not yet established. Key eligibility includes previously untreated, high‑risk, early‑stage disease; detailed T/N criteria truncated in source. Study status and timelines not provided.
About this update
Based on ClinicalTrials.gov (India locations) and saved with the original source record.
View official sourceIncomplete Cervical SCI Without Instability
October 6, 2026
Prospective multicenter observational study enrolling 50 adults with acute traumatic incomplete cervical SCI (AIS D or sensory‑only deficits) without biomechanical instability. Management follows local standard of care. Assessments at baseline, 3, and 6 months include ISNCSCI, gait/balance (10‑m walk, WISCI II), upper‑extremity measures (grip/pinch strength, GRASSP v2). PROMs (SF‑36 v2, NPS) and SCIM v3, plus key/tip pinch, at 3 and 6 months only. Optional quantitative spinal cord MRI/DTI at all timepoints per surgeon discretion. Objective is to gather data on feasibility and outcomes; no interventional comparisons or efficacy claims are specified.
About this update
Based on ClinicalTrials.gov (India locations) and saved with the original source record.
View official sourceA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
October 6, 2026
Phase 3, multicenter, randomized, double‑blind, placebo‑controlled trial of efruxifermin (EFX) in non‑cirrhotic NASH/MASH with F2–F3 fibrosis. About 1,650 participants in two cohorts: Cohort 1 (n≈750, F2–F3) with histologic endpoints at Week 52; Cohort 2 (n≈900, F3, NAS not required) with biopsy at Week 96. Randomization 1:1:1 to EFX 28 mg weekly, EFX 50 mg weekly, or placebo. Procedures include up to 12‑week screening, primary/secondary histology periods, long‑term treatment and outcomes follow‑up (up to ~240 weeks), and 30‑day post‑dose visit. Evaluates histologic improvement, fibrosis regression, and noninvasive/biochemical markers. Efficacy and safety outcomes not yet known.
About this update
Based on ClinicalTrials.gov (India locations) and saved with the original source record.
View official sourceA Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
September 28, 2026
Phase not stated. Randomized study of a 9-valent ExPEC conjugate vaccine (ExPEC9V; JNJ-78901563/VAC52416) to prevent invasive extraintestinal pathogenic E. coli disease (IED) in adults ≥60 with a urinary tract infection history in the past 2 years. IED is defined by E. coli isolated from blood/sterile sites, or from urine in urosepsis without another source. Design: inferentially seamless group-sequential. Phases: screening (up to 8 days pre–Day 1), randomization, single vaccination (Day 1), and follow-up up to 4 years; total study duration about 6 years 9 months. Rationale notes that conjugate vaccine efficacy is not expected to differ by antimicrobial resistance due to O-polysaccharide targeting. Ongoing; outcomes not reported.
About this update
Based on ClinicalTrials.gov (India locations) and saved with the original source record.
View official sourceA Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
September 28, 2026
Interventional study in India assessing safety of insulin lispro‑aabc (LY900014) in adults with type 2 diabetes mellitus. Duration ~33 weeks: screening (1 week), 4‑week lead‑in, 26‑week treatment, 2‑week follow‑up. Key eligibility includes: T2DM ≥1 year; on multiple daily injections (various basal and bolus insulins or premixed regimens) ≥90 days; up to 3 stable oral agents allowed; HbA1c 7.5%–10%; BMI ≤45 kg/m²; access to phone and refrigeration; regular wake–sleep schedule. Objective is safety evaluation; efficacy endpoints not specified here. Status not stated; no results reported.
About this update
Based on ClinicalTrials.gov (India locations) and saved with the original source record.
View official sourceThese AI summaries are a quick starting point. Check the original source, local guidance and your own clinical judgement before using them.